Glaukos Co. (NYSE:GKOS - Get Free Report) COO Joseph E. Gilliam sold 200 shares of Glaukos stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $96.57, for a total value of $19,314.00. Following the sale, the chief operating officer now directly owns 101,845 shares of the company's stock, valued at approximately $9,835,171.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Glaukos Price Performance
Shares of NYSE:GKOS opened at $96.80 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 4.78 and a current ratio of 5.34. The stock's fifty day simple moving average is $90.83 and its two-hundred day simple moving average is $79.16. Glaukos Co. has a 1-year low of $45.38 and a 1-year high of $97.77.
Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.07). Glaukos had a negative net margin of 42.79% and a negative return on equity of 22.67%. The company had revenue of $82.40 million for the quarter, compared to the consensus estimate of $81.00 million. During the same quarter last year, the business posted ($0.53) earnings per share. Glaukos's revenue was up 15.7% on a year-over-year basis. Research analysts expect that Glaukos Co. will post -2.18 EPS for the current year.
Institutional Investors Weigh In On Glaukos
Healthcare Takes A Big Step Forward With The Help Of AI
From The Bull Report | Ad
The average doctor can diagnose an illness correctly 50-90% of the time.
But one innovative company's medical AI gets it right 92%+.
Click here to see why this small company is trusted by the Mayo Clinic
Several large investors have recently made changes to their positions in GKOS. Point72 Asset Management L.P. increased its position in shares of Glaukos by 154.8% during the 4th quarter. Point72 Asset Management L.P. now owns 1,152,600 shares of the medical instruments supplier's stock valued at $50,346,000 after purchasing an additional 700,200 shares during the last quarter. Balyasny Asset Management L.P. increased its holdings in Glaukos by 304.3% in the 1st quarter. Balyasny Asset Management L.P. now owns 691,899 shares of the medical instruments supplier's stock worth $34,664,000 after acquiring an additional 520,758 shares during the last quarter. Invesco Ltd. increased its holdings in Glaukos by 45.5% in the 3rd quarter. Invesco Ltd. now owns 1,450,033 shares of the medical instruments supplier's stock worth $109,115,000 after acquiring an additional 453,756 shares during the last quarter. Norges Bank purchased a new stake in Glaukos in the 4th quarter worth about $17,593,000. Finally, Iron Triangle Partners LP purchased a new stake in Glaukos in the 2nd quarter worth about $22,075,000. 99.04% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
GKOS has been the topic of several analyst reports. Needham & Company LLC upped their target price on Glaukos from $105.00 to $108.00 and gave the company a "buy" rating in a report on Thursday, February 22nd. JPMorgan Chase & Co. upgraded Glaukos from a "neutral" rating to an "overweight" rating and upped their target price for the company from $66.00 to $91.00 in a report on Thursday, December 21st. Stifel Nicolaus reiterated a "buy" rating and issued a $110.00 target price on shares of Glaukos in a report on Wednesday. Truist Financial reiterated a "buy" rating and issued a $110.00 target price on shares of Glaukos in a report on Friday, March 22nd. Finally, Piper Sandler boosted their price target on Glaukos from $90.00 to $105.00 and gave the company an "overweight" rating in a research note on Friday, December 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $98.30.
Check Out Our Latest Analysis on Glaukos
Glaukos Company Profile
(
Get Free Report)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
